Best Healthcare Companies in Hong Kong, China
The 121 best Healthcare companies in Hong Kong, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genertec Universal Medical Group.
Ranked: Best Healthcare companies in Hong Kong
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Genertec Universal Medical Group Provider of medical information solutions | $150M | 62 mo ago | Series D | — | 1984 | — | — | — |
| 2 | Kira Pharmaceuticals R&D company focused on manufacturing of drugs for multiple therapeutic areas | $100M | 65 mo ago | Series B | Gonghua Pan Co-Founder | 2017 | PrismicNode.jsReact+7 | 28 patents Therapeutic antibodies targeting complement proteins C2 and C5a for immune modulation | — |
| 3 | Jacobson Pharma Provider of generic and specialized formulation products | $64M | 104 mo ago | Public | Kwong Yip Sum CEO | 1998 | PHPApache HTTP ServerGoDaddy | — | — |
| 4 | IDS Medical Systems An integrated medical solution provider of equipment, supplies, and services in Asia | $60M | 107 mo ago | Series B | — | 2011 | PHPRed HatYouTube+17 | — | — |
| 5 | China NT Pharma Provider of pharmaceutical distribution, bone health services, and investment platforms | $60M | — | Public | Wu Tie Chairman & CEO | 1995 | — | 847 patents Small-molecule therapeutic agents targeting protein inhibition and disease-modifying pathways | — |
| 6 | MabSpace Biosciences Platform for antibody discovery and development | $55M | 97 mo ago | Series B | — | 2013 | — | 10 patents Therapeutic antibodies against claudin‑18.2 and PD‑L1 for cancer treatment | — |
| 7 | Phase Scientific Provider of technology for diagnostics tools | $36M | 13 mo ago | Series A | Daniel Kamei Co-Founder | 2012 | — | 6 patents Nucleic acid purification and size-selective enrichment kits for RNA/DNA analysis | — |
| 8 | Uni-Bio Science Chinese bio-similar and bio-betters company | $15M | 107 mo ago | Public | — | 2001 | PHPAnimate.cssThinkPHP+3 | — | — |
| 9 | Biomedical Technology Holdings Chain of biomedical & intestinal microbiome testing services | $2M | 35 mo ago | Seed | Vincent Tsang CEO | 2018 | WordPressMySQLPHP+36 | — | — |
Top 12 Healthcare companies in Hong Kong
#1
Series A · Hong Kong, Hong Kong · founded 2012 · 20 employees$36Mraised▾
Phase Scientific provides the technology for diagnostics tools. It offers its propriety point-of-care test kits for infectious diseases, including tooth decay, hepatitis, malaria, and sexually transmitted diseases, liquid biopsy for an early stage of cancer determination, it also offers health data platform and mobile app connected to a database and analytical to manage health risks. It also offers animal health, food safety, and environmental testing.
- May 2025Series A$34M
- May 2017Grant (prize money)$749.8K
- Mar 2017Grant (prize money)$1.1M
- Jan 2016Grant (prize money)$150K
#2
Series D · Hong Kong, Hong Kong · founded 1984 · 20048 employees$150Mraised▾
Provider of medical information solutions
- Mar 2021Series D$150M
#3
Series B · Hong Kong, Hong Kong · founded 2017 · 39 employees$99.5Mraised▾
R&D company focused on manufacturing of drugs for multiple therapeutic areas
- Jan 2021Series B$53.5M
- Nov 2020Series B$46M
#4
Series B · Hong Kong, Hong Kong · founded 2013 · 60 employees$55Mraised▾
MabSpace Biosciences is focused on the discovery and early development of antibody-based therapeutics. Using its proprietary immune tolerance breaking technology (IMTB), the company provides antibody discovery services to pharma companies. The company also provides in vitro and in vivo pharmacological profiling services. Their platform can be used for the development of antibodies for the treatment of cancer, metabolic disorders, and autoimmune diseases, among others.
- May 2018Series B$40M
- Oct 2015Series A$15M
#5
Public · Kwun Tong, Hong Kong · founded 1998 · 1789 employees$64Mraised▾
Jacobson Pharma is a manufacturer of generic products. The therapeutic areas they manufacture in include cardiovascular, central nervous system, gastrointestinal, oral anti-diabetics, respiratory, etc. They manufacture a wide range of formulations such as oral solid (tablets, capsules), oral liquid (syrup, suspension), semi-solid (cream, ointment) and sterile gels (eye drops, injectables), specialized formulations (enteric-coated tablets, sustained-release tablets, and orodispersible tablets), etc.
- Oct 2017Post IPO$64M
#6
Series B · Kowloon, Hong Kong · founded 2011 · 1800 employees$60Mraised▾
IDS Medical Systems (idsMED) is an integrated medical solution provider of equipment, supplies, and services in Asia. They offer marketing solutions, biomedical engineering services, and clinical support, inventory management and logistics services. Their customer includes healthcare institutions such as government and private hospitals, day surgery centre, specialist and primary care clinics, laboratories and nursing homes. They have partnerships with Philips, Maquet, Hill-rom, Smiths Medical, Teleflex, Belimed, CAE, GE Healthcare and Trumpf.
- Jun 2017Series B$60M
#7
Seed · Hong Kong, Hong Kong · founded 2018$2Mraised▾
Chain of biomedical & intestinal microbiome testing services
- Jun 2023Seed—
- Apr 2023Seed$2M
#8
Public · Hong Kong, Hong Kong · founded 1995 · 124 employees$60Mraised▾
Provider of pharmaceutical distribution, bone health services, and investment platforms. It offers distribution services for pharmaceuticals, including vaccines. The company also operates a bone health platform integrating medicine, devices, and digital services. Additionally, it manages an investment platform focused on the healthcare sector. The business model encompasses both direct sales and distribution partnerships.
#9
Public · Hong Kong, Hong Kong · founded 2001 · 340 employees$15.4Mraised▾
Uni-Bio Science is a late clinical-stage bio-similars and bio-betters company. The company has 4 drug candidates in the pipeline. Two of them have completed trials and are in pre-registration. These are Uni-PTH (Parathyroid hormone 1-34 analog) for osteoporosis and ostealgia, and Uni-E4, a GLP-1 agonist, and a non-insulin diabetes treatment. The company has an Erythropoietin biosimilar in phase I and rExendin-4 biosimilar in preclinical phase.
- Jul 2017Post IPO$15.4M
#10
Series A · Hong Kong, Hong Kong · founded 2018—raised▾
Chain of general clinic
- Mar 2024Series A—
#11
Series A · Hong Kong, Hong Kong · founded 2007—raised▾
Standalone healthcare clinic
- Aug 2022Series A—
#12
Series A · Tsim Sha Tsui, Hong Kong · founded 2006—raised▾
Provider of business strategy, sales, and other consulting services for drug developing companies
- 2018Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.